Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Buys 84,124 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock in a transaction on Wednesday, July 22nd. The shares were bought at an average cost of $9.93 per share, with a total value of $835,351.32. Following the completion of the transaction, the director owned 17,182,603 shares of the company’s stock, valued at approximately $170,623,247.79. This trade represents a 0.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, July 23rd, Ra Capital Management, L.P. bought 59,880 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.96 per share, with a total value of $596,404.80.
• On Tuesday, July 21st, Ra Capital Management, L.P. purchased 120,582 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.

Artiva Biotherapeutics Trading Up 0.6%

ARTV stock traded up $0.06 during trading hours on Tuesday, hitting $10.38. 193,057 shares of the stock were exchanged, compared to its average volume of 388,732. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The firm has a market capitalization of $256.59 million, a P/E ratio of -2.95 and a beta of 2.18. The company has a 50-day simple moving average of $8.83 and a two-hundred day simple moving average of $7.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on ARTV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC lifted its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets grew its position in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the 4th quarter worth about $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in Artiva Biotherapeutics in the third quarter valued at about $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.